Publications of a Nobel Prize Winner: Spotlight on James P. Allison

Posted on by

The 2018 Nobel Prize in Physiology or Medicine was jointly awarded to James P. Allison and Tasuku Honjo for their research on immune checkpoint blockade as a cancer treatment therapy.

Dr. Allison was Chair of the Immunology program at the Sloan Kettering Institute from 2004–2012, during which time he authored 123 publications.

You can browse these works from Dr. Allison’s Library-curated Synapse Author Profile, exploring also his various MSK co-author collaborations. 

Some of Dr. Allison’s influential papers while conducting research at MSK:

*data retrieved from Scopus citation database, 10/9/2018

Looking for a Multi-Subject Database? Try Academic OneFile

Posted on by

With over 96,000 periodical and scholarly articles, Academic OneFile offers a wide coverage of topics such as biology, chemistry, economics, criminal justice, and more.  This resource allows users to access full-text, and export citations to bibliographic management tools like EndNote and RefWorks.

Link to Academic OneFile from the MSK Library’s Databases and if you have any questions about this resource, please don’t hesitate to ASK US.

Former MSK Researcher Wins Nobel Prize in Physiology or Medicine

Posted on by

Last Monday, Dr. James Allison and Dr. Tasuku Honjo won the Nobel Prize in the category of Physiology or Medicine for discoveries leading to the development of cancer immunotherapy drugs. As MSK’s Dr. Jedd Wolchok told the Associated Press, “An untold number of lives … have been saved by the science that they pioneered.” Dr. Allison, now at MD Anderson Cancer Center, worked on this research in part while chair of the Immunology Program at MSK.

Two articles from Vox put the research into a larger context. The first explains that with Dr. Allison and Dr. Honjo’s findings, up to 15-20 percent of patients with advanced melanoma and lung cancer can now benefit from precise checkpoint inhibitor therapies that target the proteins CTLA-4 (studied by Dr. Allison) and PD-1 (studied by Dr. Honjo). MSK’s Dr. Michael Postow explains in the article that next steps in immunotherapy research include determining who the therapies will help and why they don’t help the majority of patients.

The second Vox piece looks at the economics of checkpoint inhibitor therapy. While immunotherapies save lives, they also can cost more than $100,000 per patient. The article includes this chart from MSK’s Dr. Peter Bach:

For more of Dr. Bach’s economic comparisons, visit the website of MSK’s Center for Health Policy & Outcomes.